Gain Therapeutics reports FY2022 net loss $17.6M; cash $22.1M; GT-02287 on track for Phase 1 in H2 2023

Gain Therapeutics, Inc.

Net loss $17.6M ($1.48/share) vs $13.9M ($1.37) in 2021; R&D spend $8.4M, G&A $9.5M.
Cash and marketable securities $22.1M as of Dec 31, 2022; runway expected into Q2 2024.
GT-02287 IND-enabling studies completed H1 2023; Phase 1 dossier submission by mid-2023; Australian trial in H2 2023.
Awarded €1.2M non-dilutive grant for Alpha-1 Antitrypsin Deficiency research program.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Gain Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $140,108, net income $17.59 million, EPS $1.48.

Period: the year ended December 31, 2022
Revenue: $140,108
Net income: $17.59 million
EPS: $1.48
Result: reported results

Exact text from the filing

(audited) Year Ended December 31, 2022 2021 Revenues: Collaboration revenues $ 132,640 $ 133,928 Other income 7,468 31,066 Total revenues 140,108 164,994 Operating expenses: Research and development (8,377,290) (7,164,229) General and administrative (9,539,863) (6,826,938) Total operating

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-004458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.